Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Core Insights - Biomea Fusion, Inc. will present at ObesityWeek® 2025, showcasing preclinical data for its drug candidates BMF-650 and icovamenib [1][2] Group 1: Presentation Details - Biomea will present two posters on November 4, 2025, focusing on BMF-650's efficacy and the combination of icovamenib with semaglutide [3] - The abstracts from these presentations will be published in the peer-reviewed Obesity journal supplement [3] Group 2: Product Information - Icovamenib is a selective covalent inhibitor of menin, aimed at enhancing the function and quantity of insulin-producing beta cells, representing a potential non-chronic therapy for Type 2 Diabetes (T2D) [4] - BMF-650 is a next-generation oral small-molecule GLP-1 receptor agonist designed for obesity treatment, offering improved oral bioavailability and sustained receptor activation [5] Group 3: Company Overview - Biomea Fusion is focused on developing oral small molecule therapies for diabetes and obesity, addressing metabolic disorders that affect a significant portion of the global population [6]